3,239.72
-10.78
(-0.33%)
Jun 19 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 3,228.00 - 3,258.00 |
| 52 week | 2,648.00 - 3,544.50 |
| Open | 3,232.00 |
| Vol / Avg. | 1.51M/1.80M |
| Mkt cap | 40,436.79M* |
| P/E | 11.28 |
| Div/yield | 122.26/5.56* |
| EPS | 2.87* |
| Shares | 1,248.16M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Jun 18, 2013
AstraZeneca PLC at Citi European Healthcare Conference
Jun 13, 2013
AstraZeneca PLC at Goldman Sachs Healthcare Conference
Jun 2, 2013
AstraZeneca PLC ASCO Briefing Investor & Analyst Conference Call
May 30, 2013
AstraZeneca PLC at EBD Group ChinaBio Partnering Forum
Apr 25, 2013
Q1 2013 AstraZeneca PLC Earnings Conference Call
Apr 22, 2013
AstraZeneca PLC at Biotechnology Industry Organization (BIO) International Convention
|
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 15.85% | 22.62% |
| Operating margin | 21.88% | 29.13% |
| EBITD margin | - | 38.13% |
| Return on average assets | 7.67% | 11.90% |
| Return on average equity | 17.62% | 26.81% |
| Employees | 51,700 | - |
| Carbon Disclosure Rating | - | 73/100 |
Address
2 Kingdom Street, Paddington
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In August 2012, Alliance Pharma plc�s subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands. In August 2012, the Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company.
Officers and directors
| Pascal Soriot | Chief Executive Officer, Executive Director | |
| Simon Jonathan Lowth | Chief Financial Officer, Executive Director | |
| Lynn Tetrault | Executive Vice President - Human Resources and Corporate Affairs | |
| Ruud Dobber | Executive Vice President, Europe | |
| Marc Dunoyer | Executive Vice President, Global Portfolio & Product Strategy | |
| Paul Hudson | Executive Vice President, North America | |
| Bahija Jallal Ph.D. | Executive Vice President, MedImmune | |
| Mark Mallon | Executive Vice President, International | |
| Briggs Morrison | Executive Vice President - Global Medicines Development | |
| Menelas Pangalos | Executive Vice President - Innovative Medicines |